Awardee OrganizationUNIVERSITY OF ALABAMA AT BIRMINGHAM
Description
Abstract Text
Prolactin secreting adenomata are a common cause of amenorrhea and
infertility. tumors fortunately usually retain hormonal responsiveness such
that their hormone production and growth can be controlled by the same
hormones that modulate their normal counterparts. We have proposed that
the growth of pituitary lactotrophs is regulated by growth factors whose
expression in the pituitary gland is regulated hormonally. Previously we
have localized transforming growth factor-alpha (TGFalpha) to lactotrophs
and propose that this growth factor mediates the hormonal control of growth
via the epidermal growth factor (EGF) receptor. Indeed, we have shown that
estrogen-stimulated growth is preceded by an increase in TGFalpha mRNA in
the pituitary while, bromergocryptine mediated growth inhibition is
preceded by a decrease in TGFalpha mRNA. Our proposal is to enlarge upon
these studies. Specifically, we propose to investigate the sites of
TGFalpha expression in the pituitary and the modulation of its expression
by estrogens and dopamine agonists using in situ hybridization. We also
propose to develop transgenic mice in which TGFalpha overexpression is
targeted to the lactotroph using the segments of the prolactin promoter
which mediate- differing levels of tissue specific expression. These later
studies will show whether TGFalpha stimulates lactotroph hyperplasia and
hyperfunction. Finally, we have shown that TGFalpha expression is
upregulated by phorbol esters and EGF. We have cloned 14 kb of the
5'-flanking region of the human TGFalpha gene of which a 1 kb proximal
segment is capable of driving the expression of the luciferase reporter
gene in MDA468 cells (human breast carcinoma cells). The 5'-promoter
region of the TGFalpha gene is unusual in that it is G-C rich and does not
contain typical TPA, EGF or estrogen response elements. On the other hand,
it has striking similarity to the EGF receptor gene, which, in our systems,
is coordinately regulated with the gene for its ligand, TGFalpha. We
propose that these two genes use similar elements (cis- and trans-) to
control their expression. Based on the structure of these genes, we
believe these elements are distinct from the currently well characterized
elements in other genes, raising the potential for the characterization of
a novel transcription regulatory system. We plan to characterize the
cis-acting elements in the TGFalpha gene that mediate phorbol ester and EGF
responsiveness and to isolate and clone the proteins that interact with
these elements. Together, the proposed studies will provide insight into
the physiological role of TGFalpha in lactotroph, and form the basis for
the understanding of its role and controlling mechanisms in other tissues.
National Institute of Diabetes and Digestive and Kidney Diseases
CFDA Code
DUNS Number
063690705
UEI
YND4PLMC9AN7
Project Start Date
01-June-1991
Project End Date
31-May-1996
Budget Start Date
01-June-1994
Budget End Date
31-May-1995
Project Funding Information for 1994
Total Funding
$210,492
Direct Costs
$147,369
Indirect Costs
$63,123
Year
Funding IC
FY Total Cost by IC
1994
National Institute of Diabetes and Digestive and Kidney Diseases
$210,492
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01DK043652-04
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01DK043652-04
Patents
No Patents information available for 5R01DK043652-04
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01DK043652-04
Clinical Studies
No Clinical Studies information available for 5R01DK043652-04
News and More
Related News Releases
No news release information available for 5R01DK043652-04
History
No Historical information available for 5R01DK043652-04
Similar Projects
No Similar Projects information available for 5R01DK043652-04